Download PDF
Pharmacopsychiatry 2024; 57(06): 283-289
DOI: 10.1055/a-2375-3859
Original Paper

Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment

Kankan Qu
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
,
Yanan He
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
,
Zhongdong Zhang
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
,
Yeli Cao
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
,
Qiyun Qin
2   Genenexus Technology Corporation, Shanghai, China
,
Zhenhe Zhou
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
,
Lili Zhen
1   The affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective To determine if the cardiac function and “endocrinium” of Chinese patients are associated with dopamine D2 (DRD2) (rs6276) and DRD3 (rs6280, rs963468) genetic polymorphisms when treated with amisulpride.

Methods This study enrolled 148 patients with schizophrenia who took amisulpride orally for 8 weeks. DRD2 (rs6276) and DRD3 (rs6280, rs963468) genetic polymorphisms were detected with TaqMan-MGB allelic discrimination.

Results Analysis by multivariate covariance analysis (MANCOVA) showed that after adjusting for age, gender, and the baseline level, the increase in the level of aspartate aminotransferase (AST) and creatine kinase (CK) in the rs6276 AG group was higher than that in the AA and GG groups. Similarly, the changed estradiol (E2) level in rs6276 GG and rs963468 GG groups was higher than that in the other two groups. Adjusting for covariates, the increased triglyceride (TG) level in rs6276 GG and rs963468 GG groups was the highest among their different genotype groups. The increase in the level of “AST” in the rs6280 TT group was higher than that in the CC and CT groups upon adjusting for covariates. Similarly, MANCOVA showed that the increase in the level of “CK” in the rs6280 CT group was higher than that in the CC and CT groups. Besides, the increased level of “PRL” in the rs6280 CC group and rs963468 GG group was higher than that in their other two genotypes groups.

Conclusion DRD2 (rs6276) and DRD3 (rs6280, rs963468) polymorphisms can affect amisulpride tolerability since they are associated with the observed adverse reactions, including cardiac dysfunction and endocrine disorders in Chinese patients with schizophrenia.

Keywords

DRD2 - DRD3 - genetic polymorphisms - amisulpride - adverse reactions


Publication History

Received: 08 October 2023

Accepted after revision: 11 February 2024

Article published online:
26 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kazutoshi K, Shunsuke T, Daiki S. et al. Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultratreatment-resistant schizophrenia. Psychiatry Clin Neurosci 2023; 77: 2-11
    CrossrefPubMedGoogle Scholar
  • 2 Dandan W, Yewei W, Yan C. et al. Differences in inflammatory marker profiles and cognitive functioning between deficit and nondeficit schizophrenia. Front Immunol 2022; 13: 958972
    CrossrefPubMedGoogle Scholar
  • 3 Gianluca U, Pasquale DC, Sreya M. et al. Prioritization of potential causative genes for schizophrenia in the placenta. Nat Commun 2023; 14: 2613
    CrossrefPubMedGoogle Scholar
  • 4 Ming HZ, Zhen JL, Qiong YH. et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: A 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 2022; 9: 59
    PubMedGoogle Scholar
  • 5 Liang Y, Cao Changan, Zhu C. et al. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study. Asia Pac Psychiatry 2016; 8: 241-244
    CrossrefPubMedGoogle Scholar
  • 6 Andy KHL, Meor A, Jeanette HP. et al. Severe tachycardia associated with psychotropic medications in psychiatric inpatients: A study of hospital medical emergency team activation. J Clin Med 2021; 10: 1534
    CrossrefPubMedGoogle Scholar
  • 7 Cuifang Z, Ruofan L, Mingliang J. et al. Metformin in the treatment of amisulpride-induced hyperprolactinemia: A clinical trial. Front Mol Neurosci 2022; 15: 892477
    CrossrefPubMedGoogle Scholar
  • 8 Kankan Q, Qin Z, Lin T. et al. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: A study based on therapeutic drug monitoring data. International Clinical Psychopharmacology 2022; 37: 255-262
    PubMedGoogle Scholar
  • 9 Zubiaur P, Soria-Chacartegui P, Koller D. et al. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother 2021; 133: 111087
    CrossrefPubMedGoogle Scholar
  • 10 Koller D, Almenara S, Mejía G. et al. Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: Association with pharmacogenetics. Adv Ther 2021; 38: 1035-1054
    CrossrefPubMedGoogle Scholar
  • 11 Dos S-JA, Henriques TB, de Mello MP. et al. Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents. Int J Endocrinol 2016; 2016: 5872423
    PubMedGoogle Scholar
  • 12 Polina M, Blanca R, Alfonso B-O. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med 2021; 2: 100216
    CrossrefPubMedGoogle Scholar
  • 13 Galderisi S, Mucci A, Dollfus S, Nordentoft M. et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 64: e23
    CrossrefPubMedGoogle Scholar
  • 14 Van Munster BC, De Rooij SE, Yazdan P. et al. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 648-655
    CrossrefPubMedGoogle Scholar
  • 15 Chiesa A, Lia L, Alberti S. et al. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. Int J Psychiatry Clin Pract 2014; 18: 97-102
    CrossrefPubMedGoogle Scholar
  • 16 Zheng C, Shen Y, Xu Q. rs1076560, a functional variant of the dopamine D2 receptor gene, confers risk of schizophrenia in Han Chinese. Neurosci Lett 2012; 518: 41-44
    CrossrefPubMedGoogle Scholar
  • 17 Tomoko E, Hiroshi F, Terutaka Y. et al. TaqMan-MGB SNP genotyping assay to identify 48 citrus cultivars distributed in the Japanese market. Breed Sci 2020; 70: 363-372
    CrossrefPubMedGoogle Scholar
  • 18 Bothos E, Ntoumou E, Kelaidoni K. et al. Clinical pharmacogenomics in action: Design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS). J Transl Med 2021; 19: 151
    CrossrefPubMedGoogle Scholar
  • 19 Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526: 343-350
    CrossrefPubMedGoogle Scholar
  • 20 Cristian S, Larisa A, Bogdan-Sorin T. et al. From classic to modern prognostic biomarkers in patients with acute myocardial infarction. Int J Mol Sci 2022; 23: 9168
    CrossrefPubMedGoogle Scholar
  • 21 Jian L, Zhuo Z, Hui J, Minjie J. et al. Predictive value of elevated alanine aminotransferase for in-hospital mortality in patients with acute myocardial infarction. BMC Cardiovasc Disord 2021; 21: 82
    CrossrefPubMedGoogle Scholar
  • 22 Lazo M, Rubin J, Clark JM. et al. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol 2015; 62: 841-847
    CrossrefPubMedGoogle Scholar
  • 23 Stéphane G, Benoît F, Ould MH. et al. Monthly measurement of high-sensitivity cardiac troponins T and creatine kinase in asymptomatic chronic hemodialysis patients: A one-year prospective study. Hemodial Int 2022; 26: 166-175
    CrossrefPubMedGoogle Scholar
  • 24 Shengwei W, Yufang Z, Zhengzheng X. et al. Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: A retrospective study. Sci Rep 2021; 11: 13365
    CrossrefPubMedGoogle Scholar
  • 25 Mohamed SAH, Thamra SAG, Loai AW. et al. Hyperprolactinemia in adults treated with anti-psychotic drugs attending tertiary hospitals in Oman: An observational study. Cureus 2022; 14: e21532
    PubMedGoogle Scholar
  • 26 Eirik K, Rolf G, Farivar F. et al. Antidepressive effectiveness of amisulpride, aripiprazole, and olanzapine in patients with schizophrenia spectrum disorders: A secondary outcome analysis of a pragmatic, randomized trial (BeSt InTro). J Clin Psychopharmacol 2023; 43: 246-258
    CrossrefPubMedGoogle Scholar